非布索坦上市了吗？

It is a tablet and is an anti-gout medicine. Febuxostat has a significant inhibitory effect on both oxidized and reduced XOR, so its uric acid-lowering effect is more powerful and lasting. Therefore, this product can be used to treat chronic hyperuricemia in gout. Gout is also called hyperuricemia. As the name suggests, gout is a joint pain disease caused by high uric acid. Uric acid is an excretion. The human body produces uric acid every day and then excretes it through feces and sweat. And if there is too much uric acid, it is easy to deposit, and the main location of deposition is in the joint cavity, so pain occurs!

Febuxostat is an effective non-purine selective inhibitor of xanthine oxidase (XO). By selectively inhibiting xanthine oxidase, it can achieve the therapeutic effect of reducing serum uric acid. Uric acid is the end product of purine metabolism and is produced in the cascade reaction of hypoxanthine → xanthine → uric acid. Each step of the conversion is catalyzed by xanthine oxidase. Febuxostat has been shown to effectively inhibit both oxidized and reduced forms of xanthine oxidase. Febuxostat at therapeutic concentrations does not inhibit other enzymes involved in purine or pyrimidine metabolism, namely guanine deaminase, hypoxanthine guanine phosphoribosyltransferase, orotate phosphoribosyltransferase, orotate monophosphate decarboxylase, or purine nucleoside phosphorylase.

In April 2008, Febuxostat was approved for marketing in Europe. In February 2009, the FDA approved Febuxostat for marketing. It was officially launched in China on June 26, 2013. The launch of Febuxostat means that a new era of gout treatment has been created. The main function of Febuxostat is to inhibit the production of uric acid and promote the excretion of uric acid. Compared with other gout drugs, Febuxostat has the smallest side effects and is the latest one. Because febuxostat is highly selective, it can accurately act on enzymes, thereby reducing uric acid synthesis in the body to effectively treat gout.

Febuxostat has now been launched in major countries in the world, and India has since launched a generic version, which is extremely cost-effective and is favored by patients.